Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
22.65
-0.06 (-0.26%)
Feb 21, 2025, 3:00 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 484.84B JPY in the quarter ending December 31, 2024, with 8.48% growth. This brings the company's revenue in the last twelve months to 1.80T, up 19.46% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,795.99B JPY
Revenue Growth
+19.46%
P/S Ratio
n/a
Revenue / Employee
95.91M JPY
Employees
18,726
Market Cap
43.11B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Daiichi Sankyo Company News
- 20 days ago - AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant - Benzinga
- 21 days ago - Q3 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 21 days ago - Incoming Daiichi Sankyo CEO shares business roadmap going forward - CNBC
- 23 days ago - Daiichi Sankyo Company, Limited 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 23 days ago - Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum - Seeking Alpha
- 23 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Daiichi Sankyo reports 9M results - Seeking Alpha
- 24 days ago - Daiichi Sankyo Appoints Hiroyuki Okuzawa as Next CEO - CEOWORLD magazine